Clinical Trial

Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
Chemokine receptor CXCR4 is normally expressed on T-lymphocytes, B-lymphocytes, monocytes, macrophages, neutrophils and eosinophils as well as hematopoietic stem and progenitor cells (HSPC) in the bone marrow. 68Ga-Pentixafor PET/CT represents a promising method for the in vivo assessment of the CXCR4 expression status in cancer patients, especially in hematologic malignancies. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, risk stratification, and the prognostic evaluation in lymphoproliferative diseases.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2020-08-06; most recent amendment 2026-07-19.
Trial Details
NCT Number NCT04504526
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Lymphoma, Multiple Myeloma, Leukemia
Enrollment 50 participants
Start Date 2020-08-07
Primary Completion 2027-12 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-21